Anlotinib after surgery for non-pCR non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2 interventional trial giving anlotinib as adjuvant therapy to patients with stage IIA–IIIA non‑small cell lung cancer who received neoadjuvant PD‑1/PD‑L1 inhibitor plus chemotherapy and underwent R0 resection but did not achieve a pathological complete response. Eligible patients start oral anlotinib 4–12 weeks after surgery and are monitored for safety and signs of cancer recurrence. The study will collect clinical outcomes such as disease‑free survival and record adverse events to characterize tolerability in this postoperative setting. Results will inform whether anlotinib can reduce recurrence risk in this higher‑risk subgroup.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subjects voluntarily joined the study, signed the informed consent, and the compliance was good;
2. ≥18 years old (calculated by the date of signing the informed consent); Both men and women; ECOG score 0\~1; Expected survival ≥3 months;
3. Patients with stage IIA-IIIA NSCLC who had previously received PD-1/PD-L1 inhibitors combined with chemotherapy neoadjuvant therapy and underwent R0 resection for curative purposes before surgery (note: the disease was presented in the American Joint Committee on Cancer (AJCC)/Union International Against Cancer (UICC) 8th edition of lung cancer TNM staging);
4. For patients who did not achieve pathological complete response after PD-1/PD-L1 inhibitor combined with chemotherapy neoadjuvant treatment, and the time between the first trial medication after surgery was required to be 4-12 weeks;
5. The main organs function well and meet the standards;
6. Women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period.

Exclusion Criteria:

1. Have had or are currently suffering from other malignant tumors within 5 years. The following two conditions can be included: other malignancies treated with a single operation, achieving continuous 5-year disease-free survival (DFS); Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors \[Ta (non-invasive tumor), Tis (cancer in situ) and T1 (tumor infiltrating basal membrane)\];
2. Subjects are known to have genetic abnormalities that have been approved for targeted drug therapy (non-squamous cell carcinoma subjects are required to have EGFR or ALK gene tested or provide previous test reports during the screening period)
3. Cardiovascular and cerebrovascular abnormalities:

   1. Patients with past or existing heart failure, degree II or higher heart block;
   2. Past or present myocardial infarction or unstable angina pectoris, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
   3. Occurrence of arteriovenous thrombosis/cancer embolus events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction requiring clear diagnosis), vascular embolism (including deep vein thrombosis, arterial thrombosis, pulmonary embolism, etc.);
4. Participated in other drug clinical trials within the past 30 days;
5. Within 2 weeks before starting the administration, it has been treated with Chinese patent medicines (including compound Cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule, Xiaoaipingtablet/injection, hualbufatin capsule, etc.) with anti-tumor indications specified in the NMPA approved drug instructions;
6. Received major surgery other than radical resection of lung cancer within 4 weeks prior to initiation of administration; According to the investigator, the patient was not eligible to participate in this clinical study for other reasons.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Zhansheng
• Email: 18526812877@163.com
• Phone: 008618526812877

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining SRT and Anlotinib for treating brain metastases from lung cancer

  This study is testing if combining a targeted cancer drug called Anlotinib with a type of focused radiation therapy can help patients with non-small cell lung cancer who have limited brain metastases and haven't responded to other treatments.

  Recruiting The First People's Hospital of Lianyungang · Lianyungang, Jiangsu · NCT06476093

• Short-course radiation then tislelizumab plus anlotinib before and after surgery for stage II–IIIA lung cancer

  This study will try short-course radiotherapy followed by the immune drug tislelizumab and the targeted drug anlotinib given before and after surgery for people with stage II–IIIA non-small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06379087

• Combination treatment for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs to see if it can help people with advanced lung cancer who have certain genetic mutations live longer without their cancer getting worse.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06355609

• Combination treatment for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs for people with advanced lung cancer who have specific genetic mutations to see if it helps them live longer without their cancer getting worse.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06348927

• Combining TQB2450 injection with Anlotinib and chemotherapy for advanced lung cancer

  This study is testing if adding a new injection called TQB2450 to Anlotinib and chemotherapy can help people with advanced lung cancer who haven't responded to earlier treatments.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Huizhou, Guangdong and 4 other locations · NCT06141226

• Combining TQB2450 with chemotherapy or anlotinib for treating non-small cell lung cancer

  This study is testing if adding a new drug called TQB2450 to chemotherapy or another treatment can help people with non-small cell lung cancer do better after surgery.

  Recruiting at 7 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT05913089

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.